Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.
The clinical application of cis-diamminedichloroplatinum(II) (DDP, cisplatin) for cancer therapy is limited by its nonspecific biodistribution and severe side effects. Here, we have developed EGFR-targeted heparin-DDP (EHDDP) nanoparticles for tumor-targeted delivery of DDP. This nanoparticle delivery system possesses the following unique properties: (i) succinic anhydride-modified heparin is biocompatible and biodegradable with no anticoagulant activity; (ii) single-chain variable fragment anti-EGFR antibody (ScFvEGFR) was conjugated to the nanoparticles as an EGFR-targeting ligand. Our results showed that EHDDP nanoparticles can significantly increase the intracellular concentrations of DDP and Pt-DNA adducts in EGFR-expressing non-small cell lung cancer H292 cells via an EGFR-mediated pathway. Compared to the free DDP, significantly prolonged blood circulation time and improved pharmacokinetics and biodistribution of Pt were observed after systemic delivery of the EHDDP nanoparticles. The new EHDDP nanoparticle delivery system significantly enhanced antitumor activity of DDP without weight loss or damage to the kidney and spleen in nude mice bearing H292 cell tumors.
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
Xiang-Hong
XH
Peng
Yiqing
Y
Wang
Donghai
D
Huang
Yuxiang
Y
Wang
Hyung Juc
HJ
Shin
Zhengjia
Z
Chen
Michael B
MB
Spewak
Hui
H
Mao
Xu
X
Wang
Ying
Y
Wang
Zhuo Georgia
ZG
Chen
Shuming
S
Nie
Dong M
DM
Shin
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D066246:ErbB Receptors / Q000493:pharmacokinetics*; D006493:Heparin / Q000493:pharmacokinetics*; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D053769:Nanocapsules / Q000008:administration & dosage* / Q000737:chemistry; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007135:Immunoglobulin Variable Region; D053769:Nanocapsules; D006493:Heparin; C541485:EGFR protein, mouse; D066246:ErbB Receptors; D002945:Cisplatin